Suven Life Sciences Ltd., from Hyderabad, specializing in research on new drug candidates for central nervous system (CNS) disorders had procured two new product patents – one from the European patent office (EPO) and another from Hongkong. Both the patents claim drug compounds (New Chemical Entities- NCEs) targeting a serotonin receptor that modulates the release of different neurotransmitters. These new drug compounds will be further developed for treatment of various neurobehavioral and neurodegenerative disorders like Attention Deficit Hyperactive Disorder (ADHD), Alzheimer’s disease, Huntington’s disease, Parkinson’s disease and schizophrenia. These new drugs have a huge market potential globally and Suven Life might out-license these drugs.

The Hong Kong patent (numbered 1173140) claims 1,2-Dihydro-2-Oxoquinoline compounds as 5-Hydroxy tryptamine (a serotonin) receptor 4 modulators. Suven Life has already been granted patents for the drug compounds claimed in the Hong Kong patent in Singapore, South Africa, New Zealand, Australia, USA, South Korea, Canada and China. The EPO granted patent (numbered 2758394) claims Heteroaryl compounds that modulate the 5-Hydroxy tryptamine receptor 4. The company has filed patent applications in the national patent offices of USA, Canada and China for the drug compounds claimed in the patent granted by the EPO.